Stay updated on Sitravatinib for Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib for Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Sitravatinib for Metastatic Breast Cancer Clinical Trial page
- Check6 days agoChange Detected- Revision: v3.3.4 added; Revision: v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAdded a 'Locations' section with a Texas site; the 'Texas Locations' label was removed. The footer policy link 'HHS Vulnerability Disclosure' was removed and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now shows Revision: v3.3.2, replacing Revision: v3.3.1. This is a minor template/version update and does not modify study details or other user-facing content.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1 on the page, with no other observable changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedRemoved the banner about government funding-related information and potential delays; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check78 days agoChange DetectedThe changes are cosmetic UI/layout adjustments and minor wording changes; core trial details such as eligibility criteria, outcomes, and enrollment remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Sitravatinib for Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib for Metastatic Breast Cancer Clinical Trial page.